Novo Nordisk A/S reported a 26% growth in global sales and profits, serving over 45.2 million people affected by chronic diseases in 2024. The total remuneration for the CEO was DKK 57.1 million, and the company made significant investments of over DKK 80 billion to expand production capacity.